The phrase "adherence coverage" is not commonly used in written English and may require clarification depending on the context.
It could be used in discussions related to healthcare, insurance, or compliance, where it refers to the extent to which adherence to a treatment or policy is covered or supported.
Example: "The new policy includes adherence coverage to ensure that patients receive the necessary support for their treatment plans."
Alternatives: "compliance support" or "adherence support".
Thus, our estimates of adherence coverage exclude visits after pregnancy.
Adherence (coverage, frequency, duration, content) was assessed per intervention component during and at the end of the intervention period.
To describe average adherence coverage during the trial, we used two summary measures commonly reported in clinical trials to describe central tendency: overall study adherence and median adherence.
Adherence coverage is arguably the most relevant measure for interpreting trial results, as it provides an indication of whether sufficient study medication was taken to expect a biological response.
We recommend that trials should report measures of study medication adherence coverage (i.e. including missed visits and time off treatment), as the most relevant measure for understanding results from the intent-to-treat analysis.
Estimates of average adherence coverage during the trials ranged from 82 98 % in Mwanza, and 88 100 % in HPTN 039, depending on the summary measure and the method used to calculate it (Table 2).
Indeed, different modeling approaches using varied assumptions regarding adherence, percent coverage of ART-eligible individuals, survival, duration of infectiousness, and risk compensation arrive at different conclusions regarding the net effect of ART on preventing HIV transmission at the population level [17] [22].
The estimated decreases in HIV infections from PrEP are also in line with our earlier work [4], but are more conservative due to deliberately more pessimistic modeling assumptions, including lower estimates of PrEP efficacy, adherence and coverage, higher rates of PrEP discontinuation in susceptible individuals and significant PrEP exposure in previously-infected individuals.
As a secondary objective we analyzed the factors associated with screening adherence and coverage.
Long-acting medications are reported to offer improved convenience, confidentiality, adherence, pharmacokinetic coverage and reduced abuse potential, compared with short-acting counterparts [ 7, 22, 24, 25].
With the assistance of supercritical carbon dioxide, smooth, strong adherence and uniform coverage of Au layer was successfully electroless plated on the silk.
